Evidence map›Paper›PMID 27688611›Full record

ArticleIndian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: A timeline of clinical and microbial trends through the years.

K Govind Babu, D Lokanatha, K C Lakshmaiah, M C Suresh Babu, Linu A Jacob, Gita R Bhat, Harsha Vardhana, Mahua Sinha, B R Vijaykumar, B G Sumati and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Timing of Blood Cultures in the Setting of Febrile Neutropenia: An Australian Institutional ExperienceTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

K Govind BabuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
D LokanathaDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
K C LakshmaiahDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
M C Suresh BabuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
Linu A JacobDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
Gita R BhatDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
Harsha VardhanaDepartment of Microbiology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
Mahua SinhaDepartment of Microbiology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
B R VijaykumarDepartment of Microbiology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
B G SumatiDepartment of Microbiology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
R S JayshreeDepartment of Microbiology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.
Kidwai Memorial Institute of Oncology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFebrile neutropenia (FN) is an oncological emergency. The choice of empiric therapy depends on the locally prevalent pathogens and their sensitivities, the sites of infection, and cost. The Infectious Diseases Society of America guidelines are being followed for the management of FN in India.

methodsThis is a prospective observational study conducted at a tertiary care cancer centre from September 2012 to September 2014.

objectivesThe objectives of this study were as follows: (1) To review the pattern of microbial flora, susceptibility pattern, and important clinical variables among bloodstream infections in febrile neutropenic patients with solid tumors and hematological malignancies. (2) As per the institutional protocol to periodically review the antibiotic policy and susceptibility pattern, and compare the findings with an earlier study done in our institute in 2010. This was a prospective study conducted from September 2012 to September 2014.

resultsAbout 379 episodes of FN were documented among 300 patients. About 887 blood cultures were drawn. Of these, 137 (15%) isolates were cultured. Isolates having identical antibiograms obtained from a single patient during the same hospitalization were considered as one. Hence, 128 isolates were analyzed. About 74 (58%) cultures yielded Gram-negative bacilli, 51 (40%) were positive for Gram-positive cocci, and 3 (2%) grew fungi. Among Gram-negative organisms, Escherichia coli followed by Acinetobacter baumannii and Klebsiella pneumoniae accounted for 78% of the isolates. Among Gram-positive cocci, Staphylococcus species accounted for 84% of the isolates. We have noted a changing trend in the antibiotic sensitivity pattern over the years. Following the switch in empirical antibiotics, based on the results of the study done in 2010 (when the empirical antibiotics were ceftazidime + amikacin), the sensitivity to cefoperazone-sulbactam has plunged from about 80% to 60%%. Similar reduction in susceptibility was noted for piperacillin-tazobactam, imipenem, and meropenem. On the contrary, there was a marked increase in sensitivity to ceftazidime (50-76%). Based on these results, we have reverted to ceftazidime + amikacin as the empirical antibiotics.

conclusionEvery institute must have a regular revision of antibiotic policy based on periodic assessment of the clinical and microbiological profile in FN. This will combat antibiotic resistance.

Indexed as

Blood culture and sensitivitychanging trendsfebrile neutropeniahematological malignancysolid tumor

Identifiers

PMID27688611
PMCPMC5027790
OpenAlexW2520127373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.